Neurizon Therapeutics Limited · ASX:NUZ
Neurizon Therapeutics — PharmAust — Shareholder Meeting (November 2017)
22 slides from Neurizon Therapeutics's shareholder meeting presentation, November 2017
Slide 1: AGM Presentation (November 2017)
A AGM Presentation (November 2017) PharmAust AGM Presentation (Nov 2017) 1
Slide 2: Disclaimer
Disclaimer DISCLAIMER This presentation has been prepared by PharmAust Limited (ASX: PAA) (ACN: 094 006 023) (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat th
Slide 3: 2017 Highlights: Successfully repositioned for clinical success
2017 Highlights: Successfully repositioned for clinical success • New executive team appointed • Monepantel reformulation to address palpability • Progressed Phase II Lymphoma trial • Appointed world-class advisory team • Re-engaged with Elanco • Strategic investment in Epichem to grow revenues Phar
Slide 4: Corporate Overview
Corporate Overview • PharmAust: Clinical-stage oncology company • Lead product is Monepantel (MPL) – a repurposed drug already approved for Veterinary use • PharmAust patented MPL as a novel anticancer drug • Clinical strategy targeting MPL for both human and vet applications • Option Agreement with
Slide 5: Corporate Snapshot
Corporate Snapshot ASX Code: PAA Total Shares on Issue 146,694,903 Market Cap $8m Options (Unlisted) 42,547,078 Cash1 $2.32M Debt2 $0.47 Top 20 Own 36% Epichem Revenue $3.05M (FY17) Board/Exec Own 13% 1. As of 30 Sept, 2017 2. EFIC loan to Epichem: Mar 31, 2017 PharmAust AGM Presentation (Nov 2017)
Slide 6: Repurposing MPL for accelerated path to commercial returns
Repurposing MPL for accelerated path to commercial returns PharmAust AGM Presentation (Nov 2017) 6
Slide 7: Drug Repurposing = Capital efficient path to market
Drug Repurposing = Capital efficient path to market Typical Drug Development Phases Discovery Preclinical Phase I Phase 2 Phase 3 FDA Market 3-6 yrs 6-7 yrs 0.5-2 yrs 10+yrs. ~$1-2 billion Drug repurposing/repositioning 6yrs. ~$300 million Drug repurposing/repositioning 3-5yrs. ~$2-5 million PharmAu
Slide 8: Why MPL for Cancer
Why MPL for Cancer In vitro: MPL kills wide range of cancer cell lines MPL Approved for Animal Health In vivo: MPL monotherapy inhibits tumours in mice xenografts (pancreatic, ovarian, colorectal) In vivo: MPL combined with front-line drugs improves potency in mouse xenografts (ovarian) Comprehensiv
Slide 9: Strategy to develop MPL as a Cancer Therapeutic
Strategy to develop MPL as a Cancer Therapeutic for: - Veterinary Health - Humans PharmAust AGM Presentation (Nov 2017) 9
Slide 10: Rationale for dual clinical development strategy
Rationale for dual clinical development strategy Vet Oncology Development Human Oncology Development 1 High quality preclinical data Preclinical Clinical Development 3-5yrs. ~$2-5 million 2 Highly predictive Clinical Development Registered Product 3 Lowers Risk Early-Mid Commercialisation Later-stag
Slide 11: Companion Animal Health Market (US:2016)
Companion Animal Health Market (US:2016) US Dog/Cat Vet Care Expenditure $17b1 Populations (2016)1 Pet drug market $10.2b by 20182 (8% CAGR) 94m 90m ● 6 m dogs diagnosed with cancer US/yr Willingness to pay more for treatment3 $ ● Therapeutic market dominated by ($2K-$5K/treatment) repurposed drugs
Slide 12: Positioning MPL to address neglected cancer markets
Positioning MPL to address neglected cancer markets Decision Tree Following Pet Cancer Diagnosis Drug Needs MPL Low Cost Neglected Market Safety Efficacy Drug Needs MPL Efficacy Low Tox Relapse PharmAust AGM Presentation (Nov 2017) 12
Slide 13: Commercial Strategy: Target entire cancer market
Commercial Strategy: Target entire cancer market Neglected Market General Vet Practitioner Market Niche Vet Oncology Relapse PharmAust AGM Presentation (Nov 2017) 13
Slide 14: Epichem
Epichem PharmAust AGM Presentation (Nov 2017) 14
Slide 15: About Epichem
About Epichem ● Specialist Synthetic & Medicinal Chemistry Services ● Highly awarded West. Aust. Company (Founded 2003) ● Staff of 23 (15 PhD's) Revenues Drug Discovery & Technical Services Fine Chemicals Catalogue PharmAust AGM Presentation (Nov 2017) 15
Slide 16: Key Drivers for Epichem Growth
Key Drivers for Epichem Growth • Phase 2 Lab Expansion to meet demand • ISO17025/34 accreditations – highest ‘calibration and testing’ stds. • Targeting expansion of high margin catalogue business • Renewal of existing major contracts • Epichem: profitable business, forecast sales of ~$4m in 2018 (>
Slide 17: Next Steps and Roadmap
Next Steps and Roadmap PharmAust AGM Presentation (Nov 2017) 17
Slide 18: On-Track for Roadmap
On-Track for Roadmap Complete Phase II Lymphoma Trial in Dogs Q4 Complete MPL Reformulation Q4 Growth of Epichem Business Q4 Progress Novartis/ELANCO Option Q4 Initiate Clinical Trials in Humans and Dogs 2018 PharmAust AGM Presentation (Nov 2017) 18
Slide 19: PharmAust's Therapeutic Pipeline
PharmAust’s Therapeutic Pipeline PharmAust AGM Presentation (Nov 2017) 19
Slide 20: PAA undervalued vs peers
PAA undervalued vs peers Company Description Market Cap ($Aus)1 Anatara Lifesciences Animal/Human Health Antimicrobial (Detach) $82m (ASX: ANR) Revenues 2017 FY $1m, EBITDA -3.4m National Vet Care Consolidated Vet Practices $161m (ASX: NVL) Paradigm Bio Repurposed small molecule. Phase II $36m (ASX:
Slide 21: PharmAust's Value Proposition
PharmAust’s Value Proposition • $8m Market Cap = Enterprise Value (revenue + cash + phase II ready asset) • Developing a single product for multiple markets in human & animal health. • Validated model: Lower costs/development risks, accelerates path to multiple value accretion catalysts • Novartis A
Slide 22: Thankyou!!
Thankyou!! Check out the new webpage PharmAust AGM Presentation (Nov 2017) 22